Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 21:12:785375.
doi: 10.3389/fphar.2021.785375. eCollection 2021.

Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease

Zhonghong Yan  1 , Guanran Wang  1   2 , Xingyang Shi  1
Affiliations
Review

Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease

Zhonghong Yan et al. Front Pharmacol. .

Abstract

Chronic kidney disease (CKD) is one of the increasingly serious public health concerns worldwide; the global burden of CKD is increasingly due to high morbidity and mortality. At present, there are three key problems in the clinical treatment and management of CKD. First, the current diagnostic indicators, such as proteinuria and serum creatinine, are greatly interfered by the physiological conditions of patients, and the changes in the indicator level are not synchronized with renal damage. Second, the established diagnosis of suspected CKD still depends on biopsy, which is not suitable for contraindication patients, is also traumatic, and is not sensitive to early progression. Finally, the prognosis of CKD is affected by many factors; hence, it is ineviatble to develop effective biomarkers to predict CKD prognosis and improve the prognosis through early intervention. Accurate progression monitoring and prognosis improvement of CKD are extremely significant for improving the clinical treatment and management of CKD and reducing the social burden. Therefore, biomarkers reported in recent years, which could play important roles in accurate progression monitoring and prognosis improvement of CKD, were concluded and highlighted in this review article that aims to provide a reference for both the construction of CKD precision therapy system and the pharmaceutical research and development.

Keywords: advances; biomarkers for early diagnosis; chronic kidney disease; prognostic biomarkers; progression biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Abdel Ghafar M. T., Shalaby K. H., Okda H. I., Abo El Gheit R. E., Soliman N. A., Keshk W. A. (2020). Assessment of Two Novel Renal Tubular Proteins in Type 2 Diabetic Patients with Nephropathy. J. Investig. Med. 68 (3), 748–755. 10.1136/jim-2019-001135 - DOI - PubMed
    1. Abdelsalam L., Ibrahim A. A., Shalaby A., Osman N., Hashad A., Badawy D., et al. (2019). Expression of miRNAs-122, -192 and -499 in End Stage Renal Disease Associated with Acute Myocardial Infarction. Arch. Med. Sci. 15 (5), 1247–1253. 10.5114/aoms.2019.87095 - DOI - PMC - PubMed
    1. Aimo A., Vergaro G., Ripoli A., Bayes-Genis A., Pascual Figal D. A., de Boer R. A., et al. (2017). Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC Heart Fail. 5 (4), 287–296. 10.1016/j.jchf.2016.12.016 - DOI - PubMed
    1. Akchurin O. M., Kaskel F. (2015). Update on Inflammation in Chronic Kidney Disease. Blood Purif. 39 (1-3), 84–92. 10.1159/000368940 - DOI - PubMed
    1. Al-Kafaji G., Al-Muhtaresh H. A. (2018). Expression of microRNA-377 and microRNA-192 and T-heir P-otential as B-lood-based B-iomarkers for E-arly D-etection of T-ype 2 D-iabetic N-ephropathy. Mol. Med. Rep. 18 (1), 1171–1180. 10.3892/mmr.2018.9040 - DOI - PubMed

LinkOut - more resources